 |
市場調查報告書
商品編碼
1378701
復發或難治性瀰漫性大 B 細胞淋巴瘤市場：依藥物類型、配銷通路和地區分類Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, By Distribution Channel, By Geography |
||||||
預計到 2023 年，全球復發或難治性瀰漫性大 B 細胞淋巴瘤市場將達到 14.795 億美元，預計在預測期內（2023-2030 年）年複合成長率為 4.3%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2022年 | 2023年市場規模 | 14.795 億美元 |
| 實績資料 | 2018-2021 | 預測期 | 2023-2030 |
| 預測期年複合成長率 | 4.30% | 2030年市場規模預測 | 19.864 億美元 |
瀰漫性大 B 細胞淋巴瘤 (DLBCL) 是最常見的淋巴瘤，約佔所有非何傑金氏淋巴瘤的 25% 至 30%。此疾病表現為結節或結外部位迅速增大的腫塊或淋巴結腫大。儘管具有攻擊性，但它對化療反應良好。它會影響許多器官系統，最好由包括腫瘤內科醫師、放射腫瘤科醫師和腎臟科醫師在內的專家團隊進行管理。結外淋巴瘤可能需要放射線治療。淋巴瘤患者常報告腎臟受累。在病程早期讓腎臟科醫師介入非常重要，因為腎衰竭可能是 DLBCL 本身的併發症，也可能在治療期間出現。應仔細評估酸鹼、電解質和液體量等腎臟指標。具有不同技術基礎和作用機制的新藥的推出將有助於市場的擴大。因此，此類先進產品的市場引入預計將在預測期內推動全球復發或難治性瀰漫性大 B 細胞淋巴瘤市場的成長。
市場動態
製藥業的主要參與者專注於開發用於治療復發或難治性瀰漫性大 B 細胞淋巴瘤的平台藥物。因此，將此類先進產品引入市場預計將在預測期內推動全球復發或難治性瀰漫性大B細胞淋巴瘤市場的成長。例如，2023年9月29日，領先的生技公司再生元製藥公司（Regeneron Pharmaceuticals, Inc.）宣布，美國食品食品藥物管理局（FDA）已確認，美國食品藥物管理局（FDA）已確認患有復發/至少兩次全身治療後出現進展的難治性 (R/R) 卵泡宣布，其 odronextamab 的生技藥品核准申請(BLA) 已收到優先審查，用於治療患有性淋巴瘤(FL ) 或R/R 瀰漫性大成人患者B 細胞淋巴瘤 (DLBCL)。 FDA 的決定目標日期是 2024 年 3 月 31 日。 Odronextamab 是一種 CD20xCD3 雙特異性抗體，旨在在橋接癌細胞上表達 CD20 和 CD3 的 T 細胞，促進局部T 細胞活化和癌細胞殺傷。這是一種臨床實驗藥物。
本研究的主要特點
- 本報告對全球復發或難治性瀰漫性大 B 細胞淋巴瘤市場進行了詳細分析，並介紹了以 2022 年為基準年的預測期（2023-2030）的市場規模和年複合成長率。
- 本報告還闡明了不同區隔市場的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
- 本報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
- 該報告根據公司亮點、產品系列、主要亮點、業績和策略等參數，介紹了全球復發或難治性瀰漫性大 B 細胞淋巴瘤市場的主要參與者。
- 該報告的見解將使行銷人員和經營團隊負責人就未來的產品發布、升級、市場擴張和行銷策略做出資訊的決策。
- 全球復發或難治性瀰漫性大 B 細胞淋巴瘤市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 相關人員可以透過用於分析全球復發或難治性瀰漫性大 B 細胞淋巴瘤市場的各種策略矩陣來促進決策。
目錄
第1章 調查目的和假設
- 研究目標
- 假設
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章 市場動態、法規及趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 市場機會
- 影響分析
- 最近的趨勢
- 最近的產品發布/核准
- 合併、收購和合作
- 監管場景
- 主要進展
- PEST分析
- 波特的分析
第4章 全球復發或難治性瀰漫性大B細胞淋巴瘤市場-新型冠狀病毒感染疾病（COVID-19）的影響分析
- 經濟影響
- 新型冠狀病毒感染疾病（COVID-19）的流行病學
- 對需求和供給的影響
第5章 2018-2030 年全球復發或難治性瀰漫性大 B 細胞淋巴瘤市場（依藥物類型）
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- 其他
第6章 全球復發或難治性瀰漫性大 B 細胞淋巴瘤市場（依配銷通路），2018-2030 年
- 醫院藥房
- 零售藥房
- 線上藥房
第7章 2018-2030年全球復發或難治性瀰漫性大B細胞淋巴瘤市場（依地區）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第8章 競爭形勢
- 公司簡介
- MorphoSys US Inc.
- Bristol-Myers Squibb Company
- Karyopharm Therapeutics
- F. Hoffmann-La Roche AG
- Merck &Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Cellular Biomedicine Group Inc.
- Genmab A/S
- Incyte
- AbbVie Inc.
- Janssen Biotech, Inc.
- Pfizer Inc.
- IMV Inc.
- Overland Pharmaceuticals（CY）Inc.
- ADC Therapeutics SA
- Eagle Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
- 分析師觀點
第9章 章節
- 參考
- 調查方法
Global relapsed or refractory diffuse large B cell lymphoma market is estimated to be valued at US$ 1,479.5 Mn in 2023 and is expected to exhibit a CAGR of 4.3% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 1,479.5 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 4.30% | 2030 Value Projection: | US$ 1,986.4 Mn |
Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma that account forabout 25% to 30% of all non-Hodgkin lymphoma. This disease presents as a rapidly growing mass or enlarging lymph nodes in a nodal or extranodal site. Though aggressive, it does respond well to chemotherapy. It can affect many organ systems, and is best managed by an interprofessional team including the medical oncologist, radiation oncologist, and nephrologists. Radiation therapy can be needed in extranodal lymphomas. Kidney involvement has been well documented in patients with lymphoma. It is important to get the nephrologist involved early in the course of the disorder as renal failure is a complication of DLBCL itself, or renal failure can manifest during treatment. Careful assessment of the renal indices including acid-base, electrolytes, and volume status, should be assessed. The introduction of new drug with different technological platform and Mechanism of Action can contribute to market expansion. Thus, introduction of such advanced products in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period.
Market Dynamics
The key players in the pharmaceutical industry are focusing on development of platform based drug for relapsed or refractory diffuse large B cell lymphoma. Thus, introduction of such advanced products in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. For instance, on September 29, 2023, Regeneron Pharmaceuticals, Inc., a leading biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had accepted for Priority Review the Biologics License Application (BLA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The target action date for the FDA decision is March 31, 2024. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
Key features of the study:
- This report provides an in-depth analysis of the global relapsed or refractory diffuse large B cell lymphoma market and provides market size (US$ Mn ) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global relapsed or refractory diffuse large B cell lymphoma market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include MorphoSys U.S. Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F.Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global relapsed or refractory diffuse large B cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B cell lymphoma market
Detailed Segmentation:
- By Drug Type:
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- MorphoSys U.S. Inc.
- Bristol-Myers Squibb Company
- Karyopharm Therapeutics
- F. Hoffmann-La Roche AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Regeneron Pharmaceuticals
- Cellular Biomedicine Group Inc.
- Genmab A/S
- Incyte
- AbbVie Inc.
- Janssen Biotech, Inc.
- Pfizer Inc.
- IMV Inc.
- Overland Pharmaceuticals (CY) Inc.
- ADC Therapeutics SA
- Eagle Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Trends
- Recent Product Launches/Approvals
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER's Analysis
4. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Monjuvi
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- XPOVIO
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Polivy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Kymriah
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Yescarta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
6. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
7. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- MorphoSys US Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Karyopharm Therapeutics
- F. Hoffmann-La Roche AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Cellular Biomedicine Group Inc.
- Genmab A/S
- Incyte
- AbbVie Inc.
- Janssen Biotech, Inc.
- Pfizer Inc.
- IMV Inc.
- Overland Pharmaceuticals (CY) Inc.
- ADC Therapeutics SA
- Eagle Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
- Analysts' Views
9. Section
- References
- Research Methodology
- About us and Sales Contact
